ABSTRACT Schizophrenia (Sz) is associated with deficits in reading ability that interrelate with disturbances in early auditory and visual/oculomotor processing. This project evaluates consequences and causes of reading impairment in Sz using combined multimodal imaging, eye tracking and computational modeling. Skilled reading depends upon intact auditory and visual sensory integration, as well as higher-order cognition. Deficits in early auditory processing in Sz are indexed by impaired tone matching and auditory plasticity, as well as by impaired generation of mismatch negativity (MMN) and reflect dysfunction within subcortical and cortical components of the early auditory system. Deficits in visual sensory processing are indexed by reduced contrast and motion sensitivity, impaired generation of visual event-related potentials (ERP), reduced fMRI activation of subcortical and cortical early visual regions. Visual oculomotor deficits are reflected by increased rates of refixation in Sz, as well as impaired generation of the fixation-related potential (FRP) during reading. Processes underlying impaired oculomotor control during reading may be modeled using non-linear computational approaches, such as E-Z Reader, which evaluate effects of alterations in specific visual, lexical and oculomotor parameters on discrete eye movement measures across populations and individuals. The funded project evaluates reading performance in first-episode Sz participants to evaluate the relationship to function outcome. This supplement extends the project in two ways. First, it adds reading assessments (n=10/yr) to individuals already participating in cognitive remediation projects funded through NYS OMH clinics in order to evaluate the effectiveness of current remediation approaches. Second, it implements a visually targeted on-line remediation program that will be added to the funded project. Participants (n=10/yr) will then undergo repeat eye-tracking and FRP assessment following 30 hrs of on-line intervention. These studies will provide pilot data for future randomized, controlled clinical trials.